Latest News & Updates
Other trending news you may like to read
Pfizer’s TUKYSA Delivers Significant PFS Benefit In Phase 3 HER2CLIMB-05 Trial; Tucatinib Combo Shows Extended First-Line Outcomes For HER2+ MBC
Pfizer’s HER2CLIMB-05 trial shows TUKYSA in first-line maintenance cut disease progression risk by 35.9%, extending PFS for HER2+ metastatic breast cancer.
Vaibhavi M.
Valneva’s IXCHIQ® Shows Strong One-Year Immunity And Safety In Children, Clearing Path Toward Phase 3 Trials; Delivering Robust 12-Month Protection Against Chikunguny
Valneva reports strong Phase 2 pediatric results for its single-shot chikungunya vaccine, supporting full-dose use as it advances toward Phase 3 development.
Vaibhavi M.
Kane Biotech Gains Health Canada Approval For revyve® Antimicrobial Wound Gel Spray,Strengthening Kane Biotech’s Growing Wound Care Portfolio
Kane Biotech secures Health Canada approval for its revyve® Antimicrobial Wound Gel Spray, expanding advanced wound care options for complex and hard-to-heal wounds.
Vaibhavi M.
Roche’s Giredestrant Achieves Significant Phase III Benefit in Early ER-Positive Breast Cancer; lidERA Trial Shows Giredestrant Reduces Recurrence Risk
Roche’s oral SERD giredestrant cut invasive breast cancer recurrence risk by 30% in phase III, showing strong potential as a new standard-of-care therapy.
Vaibhavi M.
